FOXP3 and neoplasm: In the tumor tissue, though the number of Foxp3+ Tregs does not decrease, CTLA-4 expression on Tregs is downregulated and higher fractions of effector CD8+ cytotoxic T cells, IFNγ+CD4+ T cells, and CD80+ dendritic cells are observed, highlighting the notion that NR4A inhibition breaks the immune tolerance against cancer cells [82].